文献
J-GLOBAL ID:201702276228868418
整理番号:17A1716735
進展型小細胞肺癌に対するファーストライン治療としてのプラチナベース化学療法との併用におけるリロツムマブまたはガニツマブの無作為化,プラセボ対照,第1b/2相研究【Powered by NICT】
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer
著者 (15件):
Glisson Bonnie
(The University of Texas MD Anderson Cancer Center, Houston, TX)
,
Besse Benjamin
(Gustave Roussy, Villejuif, and Paris-Sud University, Orsay, France)
,
Dols Manuel Cobo
(Hospital Universitario Malaga General, Malaga, Spain)
,
Dubey Sarita
(Amgen Inc, South San Francisco, CA)
,
Schupp Marco
(Amgen (Europe) GmbH, Zug, Switzerland)
,
Jain Rajul
(Amgen Inc, Thousand Oaks, CA)
,
Jiang Yizhou
(Amgen Inc, Thousand Oaks, CA)
,
Menon Hari
(Tata Memorial Hospital, Mumbai, India)
,
Nackaerts Kristiaan
(KU Leuven, University of Leuven, University Hospitals Leuven, Leuven, Belgium)
,
Orlov Sergey
(Pavlov State Medical University, St Petersburg, Russian Federation)
,
Paz-Ares Luis
(Doce de Octubre University Hospital and CNIO, Madrid, Spain)
,
Ramlau Rodryg
(Department of Oncology, Poznan University of Medical Sciences, Poznan, Poland)
,
Tang Rui
(Amgen Inc, Thousand Oaks, CA)
,
Zhang Yilong
(Amgen Inc, Thousand Oaks, CA)
,
Zhu Min
(Amgen Inc, Thousand Oaks, CA)
資料名:
Clinical Lung Cancer
(Clinical Lung Cancer)
巻:
18
号:
6
ページ:
615-625.e8
発行年:
2017年
JST資料番号:
W3210A
ISSN:
1525-7304
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)